INTRODUCTION INTRODUCTION
• This national, multicenter, prospective, noninterventional study is assessing long-term treatment with apremilast in patients with plaque psoriasis in Germany (LAPIS-PSO; ClinicalTrials.gov: NCT02626793).
• This study aims to determine patients' quality of life and satisfaction with apremilast 30 mg twice daily (APR) treatment, as well as the clinical effi cacy of APR, in a real-world setting of patients who have previously received conventional systemic therapy.
• A subgroup analysis of the LAPIS-PSO interim analysis is presented here.
METHODS METHODS

Study Design
• The subgroup analysis was stratifi ed based on the number of prior conventional systemic treatments (≤1 vs. >1) ( Table 1 ). 
Stratifi cation
• Two subgroups were defi ned following stratifi cation: -Subgroup 1: Patients with treatment failure (lack of effi cacy or intolerance) of ≤1 prior conventional systemic treatment -Subgroup 2: Patients with treatment failure (lack of effi cacy or intolerance) of >1 prior conventional systemic treatment
End Points
Primary End Point • The primary end point was the percentage of patients achieving Dermatology Life Quality Index (DLQI) score ≤5 or improvement from baseline in DLQI score by ≥5 points at Visit 2.
Secondary End Points (Interim Analysis at Visit 2)
• Percentage of patients achieving DLQI score ≤5 or improvement from baseline in DLQI score by ≥5 points at all other visits • Effi cacy on skin: Physician's Global Assessment (PGA) and body surface area (BSA) involvement
• In addition, the following were assessed: -Scalp involvement -Nail involvement -Patient's Global Assessment (PaGA)
• Safety and tolerability
RESULTS RESULTS
Patient Demographics and Disease Characteristics
• Baseline patient demographics and disease characteristics for the full analysis set (FAS) are shown in Table 1 . Effi cacy on Nail Psoriasis: Target-Nail Psoriasis Severity Index (Target-NAPSI)
• The mean (SD) Target-NAPSI in subgroup 1 (4.0 [2.06]) was better than that in subgroup 2 (4.6 [2.53]).
• The mean (SD) percentage change in Target-NAPSI was −58.22% (53.423) in subgroup 1 and −48.61% (37.241) in subgroup 2.
• Target-NAPSI-50 response was identical between subgroups at Visit 2 (66.7%) (Figure 3 ). • Scalp manifestation was comparable at baseline and had slightly greater improvements in subgroup 1 at ~4 months.
Safety
• The overall incidence of AEs (Table 3 ) is lower than that in clinical studies.
• Only 1 patient was affected by severe AEs (obstipation, tremor, palpitations). • The most common AE was diarrhea (8.3%) ( Table 4 ). 
RESULTS (cont'd) RESULTS (cont'd)
CONCLUSIONS CONCLUSIONS
• The LAPIS-PSO interim analysis presents the fi rst data on APR for the treatment of patients with moderate to severe plaque psoriasis under routine clinical care in Germany.
• This interim analysis suggests that the effi cacy of APR in daily practice is comparable to clinical trial results and responses may be improved in patients who have received fewer prior conventional systemic therapies.
• Patient quality of life is rapidly and signifi cantly improved by APR (as shown by DLQI response within 4 weeks at Visit 1).
• The safety profi le in this real-world setting was consistent with clinical trials of APR in psoriasis. 2, 3 • There was a signifi cant improvement in disease in both subgroups.
